glp-1 nausea class action in west virginia Understanding Medications Patients Are Suing Over Alleged

Anti-obesity medications such as orlistat, phentermine-topiramate, and naltrexone-bupropion have induced a weight loss of no more than 10%, which is insufficient to prevent the risk of ORCVDs

Prescription Channel Dominates Nutritional Distribution The Rx segment held 68.5% of industry share in 2024 and is projected to grow to 72% in 2025

PROBIOTIC+ Helps keep digestion steady

macular degeneration is only one

Key updates include: Annual screening for overweight and obesity Confirmation of excess adiposity beyond BMI when feasible Clear recognition that 57% weight loss improves glycemia and cardiometabolic risk Importantly, pharmacologic obesity treatment now emphasizes: Individualized dose titration Balancing efficacy with tolerability Considering alternative agents when response plateaus GLP-1 receptor agonists and dual GIP/GLP-1 therapies now sit at the center of metabolic care